Background Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.
Introduction
Multiple sclerosis includes both inflammatory and neuro degener ative pathological mech anisms in the CNS. Neuro degenerative features form the dom inant substrate of progressive multiple sclerosis and manifest clinically by irreversible accumulation of disa bility. 1 Progressive mult iple sclerosis is the major cause of diseaseassociated costs, both to individuals and health care systems 2 and, therefore, it is a key target for thera peutic development. However, by contrast with the range of treatments that mitigate inflammatory activity in relapsingremitting multiple sclerosis, treat ments that can slow, stop, or reverse progressive multiple sclerosis are limited.
The diverse pathobiological mechanisms that contri bute to neuroaxonal loss in progressive multiple sclerosis provide a range of potential targets. Important proof ofconcept findings have emerged for drugs that have anti inflammatory mechanisms of action, such as siponimod 3 and ocrelizumab. 4 In parallel, evidence has been accumu lating for a range of candidate therapies that target key molecular processes in the axon itself, represent ing a more direct or downstream approach to achieve neuro protection. Over the past three decades, many negative trials have been published, with the findings attrib utable in part to suboptimum trial design. 5 However, the fun damental question of whether direct targeting of axonal patho biological features can be an effective therapeutic strategy remains unanswered.
Research in context
Evidence before this study We have previously published a systematic review and synthesis of available evidence for candidate oral neuroprotective drugs tested in clinical trials from patients with multiple sclerosis, dementia, motor neuron disease, Huntington's disease, and Parkinson's disease, combined with in-vivo data from experimental autoimmune encephalomyelitis (EAE) studies. We did two further searches in Ovid MEDLINE and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily (from 1946 to Feb 27, 2019) , OVID Embase (from 1980 to 2019 week 8), the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials (CENTRAL). In the first search, we used a combination of keywords and database-appropriate subject headings for the trial drugs: "amiloride" OR "fluoxetine" OR "riluzole" AND "multiple sclerosis" OR "experimental allergic encephalomyelitis" OR "EAE". We excluded symptomatic human studies. We did not restrict our search by language. In the second search, we used a combination of keywords and database-appropriate subject headings for neurodegenerative neurological diseases, including "multiple sclerosis" OR "Parkinson's disease" OR "amyotrophic lateral sclerosis-motor neuron disease" OR "Huntingdon's disease" OR "dementia", combined with terms to retrieve multiarm drug trials and the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (sensitivity and precision-maximising version, 2008 revision). We excluded symptomatic, dose-ranging, non-drug trials or studies of relapsing-remitting multiple sclerosis. We did not restrict our search by language. The first search retrieved five experimental studies for amiloride, indicating potential neuroprotection in animal models and human pathological samples. The most likely mechanism was blockage of ASIC1. In a clinical trial of primary progressive multiple sclerosis (n=14), a significant reduction was noted in the rate of whole-brain volume change with amiloride as well as improvements in deep grey and white matter tract diffusion indices. In three EAE studies, fluoxetine partly ameliorated paralysis and reduced inflammatory foci. Findings of two MR spectroscopy studies in humans showed an increase in N-acetylaspartate variables with fluoxetine, suggesting improved neuronal energetics and microstructural integrity by diffusion MRI, although a third study showed no change in markers of phosphocreatine metabolism. In a small placebo-controlled study, patients with relapsing multiple sclerosis treated with fluoxetine showed a trend towards a reduction in the number of new enhancing lesions over time. In a pilot study in progressive multiple sclerosis (n=42), non-significant benefits were seen in some markers of clinical progression with fluoxetine, although the study was underpowered. Riluzole reduced the severity of inflammation, demyelination, and axonal damage in a myelin oligodendrocyte glycoprotein-induced EAE system. In a run-in study in 16 patients with primary progressive multiple sclerosis, a reduction was noted in the rate of cervical atrophy and new T1 hypointense lesions with riluzole. In another study, no effect was seen on the atrophy rate in early multiple sclerosis with riluzole. The second search for multiarm drug trials in neurodegenerative diseases retrieved three studies. The first study in patients with progressive multiple sclerosis (n=58) assessed cyclophosphamide, adrenocorticotropic hormone, and plasma exchange. In the second study, 782 patients with early Parkinson's disease were randomly allocated to approved treatments (levodopa and DOPA decarboxylase inhibitor alone; levodopa, DOPA decarboxylase inhibitor, and selegiline; or bromocriptine). The third study was a three-arm trial of tianzhi granule, donepezil, or placebo in improving functional ability in vascular dementia. No other multiarm trials were retrieved by our search.
Added value of this study
In the MS-SMART trial, we chose three agents (amiloride, fluoxetine, and riluzole) to target different mechanistic pathways in patients with secondary progressive multiple sclerosis. We used a multiarm design to enable simultaneous assessment of these drugs at the important phase 2b decision point and, therefore, to accelerate the drug discovery process. The study design was robust with appropriate performance characteristics. We did not find any evidence of a neuroprotective effect of the three agents, despite positive early work in animals and humans.
Implications of all the available evidence
Multiarm trials are feasible and efficient in neurodegenerative diseases. They have the potential to examine promising experimental and early-phase agents in a timely fashion. The results of our study have implications for future experimental paradigms. This style of approach is necessary to accelerate treatment discovery in an area in which limited progress has been made.
A further issue for adequate testing of an axonaltargeted neuroprotective strategy in people with prog ressive mul tiple sclerosis is the predictive value of drug selection from a large array of candidates. We did a systematic review and synthesis of available evidence for candidate oral neuroprotective drugs tested in clinical trials from patients with multiple sclerosis, dementia, motor neuron disease, Huntington's disease, or Parkinson's disease, combined with invivo data from experimental allergic enceph alitis (EAE) studies. 6 This approach resulted in a shortlist of seven candidate drugs with different mechanisms of action that might prove beneficial in progressive multiple sclerosis: ibudilast, oxcarbazepine, pirfenidone, polyun saturated fatty acids (including lipoic acid), amiloride, fluoxetine, and riluzole. This strategy was ultimately confi rmed by positive phase 2 results for two of the drugs, ibudilast 7 and lipoic acid. 8 Based on our previous work, 6 we aimed to test the efficacy of targeting axonal pathobiological features as a strategy to achieve neuroprotection in progressive mul tiple sclerosis. To maximise efficiency of testing and accelerate drug development, we used a multiarm approach that enabled simultaneous assess ment of several drugs at the important phase 2b decision point, a strategy that has been used successfully in oncology. 9 Based on efficacy and drug supply, we selected three drugs from our candidate short list (amiloride, fluoxetine, and riluzole) for assessment against placebo.
Amiloride, widely used as a potassiumsparing diuretic, is an acidsensing ion channel blocker. 10, 11 ASIC1 opens in response to inflammationinduced acidosis, causing sodium and calcium influxes. 10 This action is associated with axonal injury in postmortem studies of patients with acute multiple sclerosis, 11 and blockade of ASIC1 with amiloride reduces axonal damage and improves clinical outcomes in rodent models. 10 A pilot study in individuals with progressive multiple sclerosis showed a significant reduction in wholebrain atrophy. 12 Fluoxetine, a selective serotonin reuptake inhibitor used for depression, has pleiotropic neuroprotective effects stimu lating glycogenolysis and improving mitochondrial energy metabolism. 13, 14 In an underpowered negative trial, fluoxetine showed nonsignificant benefits in some mark ers of clinical progression. 15 Riluzole, licenced for motor neuron disease, reduces gluta mate release and antagonises voltagedependent sodium channels. 16 Glutamate excito toxicity results in neu ronal injury 17 and its blockade in EAE reduces clinical impair ment and axonal damage. [18] [19] [20] In a pilot study of rilu zole in people with progressive multiple sclerosis, a reduc tion in the rate of cervical cord atrophy and the number of new brain T1 hypointense lesions was rec orded, 21 although findings of another study in individuals with early relapsingremitting multiple sclerosis or clinical isolated syndrome did not show a reduction in the rate of atrophy. 22 The Multiple SclerosisSecondary Progressive Multi Arm Randomisation Trial (MSSMART) is a phase 2b, multi centre, multiarm, parallel group, doubleblind, ran dom ised placebocontrolled trial. We used the rate of brain atrophy to assess the putative neuroprotective effect of amiloride, fluoxetine, and riluzole in people with sec ondary progressive multiple sclerosis. 23 Our aim was to efficiently test the efficacy of targeting axonal pathobiology as a strategy to achieve neuroprotection in progressive multiple sclerosis.
Methods

Study design and participants
We did an investigatorled, multiarm, parallel group, doubleblind, randomised placebocontrolled trial of amil or ide, fluoxetine, or riluzole versus placebo at 13 neuro science centres in the UK. We screened patients for enrol ment and included those aged 25-65 years with a diagnosis of secondary progressive multiple sclerosis, confirmed as per usual clinical practice. [24] [25] [26] Major inclusion criteria were an Expanded Disability Status Scale (EDSS) score between 4·0 and 6·5, evidence of steady disability progression in the preceding 2 years (with either an increase of at least 1 point in EDSS score or a clinically documented increase in disability), and no concurrent use of diseasemodifying therapies (standard UK practice for patients with secondary progressive multiple sclerosis). Patients were ineligible for the study if they had primary progressive multiple sclerosis, signifi cant depression (Beck's Depression Index II score >19), major comorbidity, glaucoma, or epilepsy; were not able to undertake MRI; had a relapse or had been treated with corticosteroids within 3 months of screening; or used immunosuppressants, diseasemodifying treatments, or experimental drugs within the previous 6 or 12 months (depending on the agent). Further details on the proto col, eligibility criteria, and study design are available elsewhere 23 and in the appendix (pp 2-3).
The study was done in accordance with the Declaration of Helsinki and International Council for Harmonisation Good Clinical Practice guidelines. Independent ethics approval for the protocol was granted by REC 13/SS/0007, and all patients provided written informed consent before entering the study. Safety oversight was the respons ibility of the Data Monitoring Committee, which reviewed accruing participantlevel data every 6 months. Individual site medical monitoring was also mandated.
Randomisation and masking
Within 30 days after screening for enrolment to the study, we randomly allocated patients (1:1:1:1) at base line either amiloride, fluoxetine, riluzole, or placebo. A research nurse used a centralised webbased service pro vided by the Edinburgh Clinical Trials Unit (Usher Institute, University of Edinburgh, Edinburgh, UK) to randomly assign inter ventions, with mini mis ation by sex, age (<45 years vs ≥45 years), EDSS score at randomisation (4·0-5·5 vs 6·0-6·5), and trial site. The mini misation procedure incor p orated a random ele ment whereby the assigned See Online for appendix treatment was switched with a probability of 10% from the group that would give greatest balance to one of the other three study groups (with a probability of 3·33% for each of the other study groups). Amiloride, fluoxetine, riluzole, and placebo capsules were overencapsulated and identical in appearance. Patients and investigators, including MRI analysts, treating clini cians, and inde pendent assessing neurologists were unaware of treat ment allocations and had no access to randomisa tion codes. We asked patients and clinicians to complete a questionnaire at week 96 to assess the validity of the masking procedures.
Procedures
We initially administered assigned treatments orally once daily, from baseline (week 0) for 4 weeks, then patients received doses twice daily from week 4 until week 96. Doses were amiloride hydrochloride 5 mg, fluoxetine 20 mg, riluzole 50 mg, or matching placebo. After the baseline visit, patients were seen at weeks 4, 8, 12, 24, 36, 48, 72, and 96, with a final safety telephone call at week 100. Brain MRI was done at screening for enrolment, week 24, and week 96. Neurological assess ments were done at screening, baseline, week 48, and week 96. Safety blood tests were assessed at every study visit and included full blood count, electrolytes, and liver and renal function tests.
Study treatment was discon tinued if confirmed repeat meas urements showed the following blood test concen trations: potassium less than 2·8 mmol/L or more than 5·5 mmol/L; sodium less than 125 mmol/L; alanine amino transferase, aspar tate amino transferase, or γglutamyl trans ferase more than five times the upper limit of normal; creatinine more than 130 μmol/L; neutrophil count less than 1·0 × 10⁹ cells per L, platelet count less than 50 × 10⁹ cells per L; or haemoglobin less than 80 g/L. Adverse events were assessed at every study visit.
Outcomes
The primary endpoint was the percentage brain volume change (PBVC) between baseline and 96 weeks, which is the standard primary outcome in phase 2 trials in pro gressive multiple sclerosis. We used the Structural Image Evaluation using Normalization of Atrophy (SIENA) method. 27, 28 SIENA is an automated method that registers the followup scan to the baseline scan and produces an integral of the edge motion occurring in each voxel between scans and directly calculates the PBVC from those values.
MRI secondary endpoints were counts of new or enlarg ing T2 lesions at 96 weeks and PBVC at 24 weeks. The core MRI protocol included fluidattenuated inver sion recovery (FLAIR), proton density, and T2 and volu metric T1weighted . Two patients withdrew after the 96-week MRI scan but before the end of the study (one allocated riluzole and one allocated placebo) and were included in the primary analysis. Two patients allocated riluzole also received fluoxetine prescribed by their family doctor towards the end of the trial. One patient allocated riluzole was withdrawn by a clinician: all other withdrawals were the patient's decision. 547 ). Neuropathic pain scores were also obtained and will be reported separately. The Multiple Sclerosis Functional Composite Zscore was norm alised (signed squareroot transformed) using partici pants' baseline scores.
Statistical analysis
The sample size calculation for the trial was based on a study from Altmann and colleagues. 29 The percentage of expected total cohort dropouts was based on two phase 2 studies in secondary progressive multiple sclerosis, 30, 31 from which we calculated that including 110 patients per Time since progression (years) 6 (4-11) 5 (3-10) 6 (4-10) 5 (3-10) 6 (3-10)
Beck Depression Index II score 6 (4-9) 6 (3-10) 7 (4-12) 7 (4-12) 6 (4-11)
Multiple Sclerosis Functional Composite score (Z-score)
Multiple Sclerosis Impact Scale 29 items version 2
At least one relapse in past 2 years 15 (14%) 9 (8%) 6 (5%) 12 (11%) 42 (9%)
Baseline normalised brain volume (mL)
Data presented are n (%), mean (SD), or median (IQR). No data were missing for the 9-Hole Peg Test, Multiple Sclerosis Impact Scale 29 items version 2, and EQ-5D-5L (VAS score); for the remaining variables, varying amounts of data were missing up to a maximum of 12 patients overall (maximum five for amiloride, two for fluoxetine, three for riluzole, and four for placebo). EQ-5D-5L=EuroQol five dimensions five levels. VAS=visual analogue scale. study group would provide 90% statistical power in the analysis of covariance to detect a 40% reduction in PBVC versus placebo, allowing for 10% dropouts plus 10% of participants discontinuing treatment while remaining in followup. Baseline data were described by summary statistics. A multiple regression model was fitted to the PBVC outcome variable, with study group as an explan atory factor (using placebo as the reference cate gory), adjust ing for baseline normalised brain volume and the minimis ation variables (age, sex, treatment centre, and EDSS score at randomisation). The multicentre trial design was taken into account by adjusting for treatment centre as a fixed effect. For each pairwise compari son of active treatment versus control, we calculated the mean difference in PBVC. Additionally, we used the method of Dunnett to adjust 95% simul taneous CIs, 32 to allow for multiple pairwise comparisons to a common con trol group and maintain the overall familywise error rate below 5%. Dunnettadjusted p values are rep orted for the primary outcome analyses. 33, 34 The prim ary analysis was a completecase analysis based on the intentiontotreat population. The intentiontotreat popu lation included all patients in the MSSMART trial who underwent randomisation and had data avail able at week 96.
The effects of missing data or outliers on the primary outcome findings were investigated by doing three sensi tivity analyses. These entailed excluding outliers more than 4 SD away from the mean, imputing missing data using a standard multiple imputation method, and imputing missing data under a missingnotatrandom assump tion, whereby a constant value was added to the values imputed using multiple imputation equal to the observed SD in the primary outcome at 96 weeks.
A further primary outcome analysis was done in the perprotocol population, which included participants who were adherent to the protocol and compliant with the originally assigned treatment throughout the duration of followup. Patients were judged compliant with the assigned treat ment if they reported taking, on average, 90% or more of their prescribed medication (taking account of planned downtitrations and deferred up titrations) in the 30 days preceding every clinic visit.
Secondary outcome analyses were not adjusted for multiple comparisons and used 5% as the nominal signifi cance level. The number of new or enlarging T2 lesions detected at the 96week MRI scan was compared between each of the three active treatment groups and placebo by means of an overdispersed Poisson regression model fitted to the number of new or enlarging T2 lesions at 96 weeks, with adjustment for minimisation variables.
For continuous or ordinal outcomes measured at 96 weeks (ie, the EDSS score, the 9Hole Peg Test, the Paced Auditory Serial Addition Test, the Multiple Sclerosis Functional Composite score, the Symbol Digit Modalities Test, Sloan low contrast visual acuity, the Multiple Sclerosis Impact Scale 29 items version 2, the Multiple Sclerosis Walking Scale version 2, the Neurological Fatigue Index, and healthrelated quality of life), we used a multiple linear 
Normalised brain volume at baseline (mL)
PBVC at 96 weeks* Adjusted mean difference in PBVC vs placebo (95% CI) † p value †
Data are mean (SD) unless otherwise stated. PBVC=percentage brain volume change. *Negative values indicate reductions in brain volume. †Adjusted for minimisation variables (age, sex, study centre, and EDSS score at randomisation) and baseline normalised brain volume, and accounted for multiple testing versus a common control group using Dunnett's method. 
High contrast (100%) visual acuity
1·0 (0·6 to 1·5) 0·81 Data are mean (SD). Results are derived from a model analysing data for 393 participants who had at least some 96-week outcome data. Numbers of patients are the maximum per group; the minimum sample size was n=380 for each secondary outcome (minimum per group: amiloride, n=98; fluoxetine, n=94; riluzole, n=92; placebo, n=94). The multiple regression model for each outcome included randomised treatment as an explanatory factor variable (with placebo as the reference category), the baseline measurement, and minimisation variables (age, sex, treatment centre, and Expanded Disability Status Scale score at baseline). EQ-5D-5L=EuroQol five dimensions five levels. VAS=visual analogue scale. *Effect sizes are adjusted mean difference (95% CI), except for new or enlarging T2 lesions, which is the adjusted rate ratio (investigational drug:placebo) and 95% CI. †95% CIs calculated using 1000 bootstrap resamples. ‡The Multiple Sclerosis Functional Composite score was signed square-root transformed before analysis. Table 3 : Secondary outcomes at 96 weeks regression method to calculate adjusted mean differences and 95% CIs for the individual comparisons between each active treatment and placebo. Regression models were adjusted for baseline and the minimisation variables.
For the EDSS outcome only, 95% CIs were calculated using a bootstrap method due to the ordinal nature of the out come variable. Cox proportionalhazard models adjusting for the minimisation variables were used for timetofirst relapse and the Timed 25Foot Walk test at 96 weeks. Analyses were done using SAS version 9.4 (SAS Institute, Cary, NC, USA).
This trial is registered with ClinicalTrials.gov, NCT01910259.
Role of the funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.
Results
The study began in December, 2014, and ended in July, 2018. We screened 547 individuals for enrolment to the study, of whom 102 were judged ineligible or dec lined to partici pate (figure 1). Between Jan 29, 2015, and June 22, 2016, we randomly allocated 445 patients with secondary progress ive multiple sclerosis either amiloride (n=111), fluoxetine (n=111), riluzole (n=111), or placebo (n=112). Baseline demo graphic characteristics were compar able between study groups, including wholebrain and T2 lesion volumes (table 1). The percentage loss to followup was 5-9% across study groups. Primary out come data at 96 weeks were available for 393 (88%) of 445 participants, 99 of whom were assigned amiloride, 96 fluoxetine, 99 riluzole, and 99 placebo. Figure 2 shows the primary outcome of PBVC at 96 weeks. The adjusted mean PBVC did not differ between each active treatment and placebo (table 2). Findings of sensitivity analyses accorded with the primary analysis results (appendix p 4).
At 96 weeks, the mean number of new or enlarging T2 lesions in patients assigned placebo was 3·0 (SD 6·9; median 0 [IQR 0-2]). Compared with placebo, a similar number of new or enlarging T2 lesions were detected at the 96week MRI scan for amiloride (rate ratio [RR] 1·2, 95% CI 0·8-1·8; p=0·29) and for riluzole (1·0, 0·6-1·5; p=0·81). Fluoxetine had fewer new or enlarging T2 lesions compared with placebo (RR 0·5, 95% CI 0·3-0·9; p=0·012).
The PBVC at 24 weeks was greater for patients assigned fluoxetine than for those allocated placebo (adjusted mean difference -0·31, 95% simultaneous CI -0·60 to -0·02; Dunnetadjusted p=0·032), but not for the other active treatment groups versus placebo. No difference was noted between active treatment groups and placebo for PBVC between 24 weeks and 96 weeks (appendix p 4). Secondary outcomes accord with insufficient evidence of therapeutic effect (table 3) . Although five of 60 clinicianreported and patientreported outcome comparisons against placebo were significant (p<0·05), this finding is similar to what we would expect due to random chance when testing all 60 comparisons each at the 5% significance level. 51 (11%) of 445 patients had at least one relapse during the study, with 16 (14%) having a relapse in the amiloride group, ten (9%) in the fluoxetine group, 11 (10%) in the riluzole group, and 14 (12%) in the placebo group. Compared with placebo, time to first relapse did not differ for amiloride (hazard ratio [HR] 1·14, 95% CI 0·56-2·35), fluoxetine (0·74, 0·33-1·66), or riluzole (0·78, 0·35-1·73). Similarly, compared with placebo, the Timed 25Foot Walk test did not differ for amiloride (HR 0·82, 95% CI 0·61-1·12), fluoxetine (0·81, 0·59-1·10), or riluzole (0·84, 0·61-1·13).
Findings of the clinician and patient masking question naire indicated that treatment assignments had been masked successfully: 51% of patients and 59% of clini cians who made a guess regarding active treatment or placebo status were correct (κ=0·04, 95% CI -0·06 to 0·14; and κ=0·13, -0·01 to 0·26; respectively). Secondary out comes at 48 weeks are reported in the appendix (pp [11] [12] . Concomitant drugs taken throughout the duration of the trial are listed in the appendix (p 13).
Our study population showed deterioration in several outcomes over the 96week period (appendix pp 5-10). For example, in the placebo group, little change was noted between baseline and week 96 in the Paced Auditory Serial Addition Test, the 9Hole Peg Test, the Symbol Digit Modalities Test, high contrast (100%) visual acuity, and Sloan low contrast visual acuity (contrast 5%), but No emergent safety issues were recorded with the active treatments. Adverse and serious adverse events are shown in table 4 and in the appendix (pp 14, 15) . Three deaths occurred during the study, which were judged by the Data Monitoring Committee unrelated to allocated treatments. One patient assigned amiloride died from metastatic lung cancer, one patient assigned riluzole died from ischaemic heart disease and coronary artery thrombosis, and one patient assigned fluoxetine had a sudden death (primary cause) with secondary causes of death listed as multiple sclerosis and obesity in the coroner's report.
Discussion
The findings of MSSMART, a large, multicentre, multi arm randomised trial in patients with secondary prog r es sive multiple sclerosis, showed that none of the three study drugs (amiloride, fluoxetine, and riluzole) had any effect on the primary outcome of PBVC over 96 weeks or any second ary outcomes, compared with placebo. Significant effi ciency gains with respect to the study des ign were, however, seen in terms of people, time, and eco nomic resources. The study cohort was typical of patients with nonrelapsing secondary progressive multiple sclerosis, with a median disease duration of 21 years (IQR 15-29), median secondary progression of 6 years (3-10), use of unilateral support when walking (median EDSS score 6·0 [5·5-6·5]), and more than 90% of patients were relapsefree for at least 2 years before recruit ment. High levels of retention (>90%) and adherence were reported, and ontrial behaviour was also typical of patients with nonrelapsing second ary progressive multiple sclerosis, with low levels of inflammatory disease activity clinically (11% of patients had an onstudy relapse) and radio logically (mean number of new or enlarging lesions was 3·0 [SD 6·9], median 0 [IQR 0-2]). Clear radio logical progression was seen, with PBVC of roughly -0·7% per year.
Taken together with the effectiveness of our trial masking and the meeting of all previous assumptions underlying our power calculations, MSSMART was sensitive to detect any neuroprotective effect of the three drugs tested. Some data were missing, 12% for the Patients experiencing at least one suspected unexplained serious adverse reaction 0 (0%) 0 (0%) 1 (1%) 0 (0%) Data are number of patients experiencing each type of event (% of cohort). Adverse events occurring in at least 5% of patients in any study group are shown. Serious adverse events occurring in at least 3% of patients in any group are shown. Full data are provided in the appendix (pp [14] [15] . The safety population comprised all patients who underwent randomisation, excluding two patients allocated riluzole who were prescribed fluoxetine by their family doctor towards the end of the trial (protocol deviation); these patients had five adverse events and no serious adverse events; a few of the adverse events occurred after fluoxetine was prescribed and, therefore, might be attributable to fluoxetine rather than riluzole (or a combination of the two). Progressive change due to secondary progressive multiple sclerosis in motor, sensory, balance, sphincter (including urinary tract infections), vision, cognitive, and fatigue levels were not reported as adverse events, serious adverse events, or suspected unexplained serious adverse reactions. Relapses were not reported as adverse events, serious adverse events, or suspected unexplained serious adverse reactions but are collated separately. *For example, abnormal blood results or weight loss. primary endpoint and as high as 15% for some secondary endpoints; although this shortfall brings some potential for bias, sensitivity analyses were supportive of the findings of the primary analysis. Drug selection in our study was based on findings of two separate systematic reviews: 6 first, we looked at preclinical studies of demyelination, inflammation, axonal loss, and neurobehavioural changes in EAE models of multiple sclerosis; second, we assessed clinical evidence at phase 2a in patients with multiple sclerosis and other neuro degenerative disorders that share common pathways of neurodegeneration. We did not select agents with clinically significant safety profile issues, those most likely to produce only symptomatic benefit, drugs with an immuno suppressive mechanism of action, agents with limited efficacy data or biological plausibility, and those that had been assessed previously in patients with relapsing remitting multiple sclerosis.
After initial identification of 120 potential candidates, two further important review steps led us to identify seven drugs for analysis: ibudilast, oxcarbazepine, pirfenidone, polyunsaturated fatty acids (including lipoic acid), amiloride, fluoxetine, and riluzole. Ibudilast and lipoic acid have now shown phase 2 success, confirming the predictive value of our candidate selection method ology. 7, 8 Pharmacokinetic considerations (eg, limited bio avail ability in the CNS) are also of potential relevance to the results of our trial. However, riluzole and fluoxetine have known CNS effects at the doses used and are established drugs for treatment of motor neuron disease and dep ression, respectively. Amiloride has a primary nonCNS target; however, the dose used was based on an earlier phase 2a trial.
The mechanisms of action of the three drugs we tested (accepting that there are likely to be additional offtarget effects of these drugs) mainly target distinct possible axonal pathobiological features implicated in the neuro degenerative substrate of progressive multiple sclerosis. Amiloride blocks acidsensing ion channels and, there fore, targets axonal calcium overload; riluzole targets glutamatemediated excitotoxic injury; and fluox etine stimulates astrocytic lactate release. Fluoxetine aims to provide essential energy substrates to neurons. 13, 14 Although all these processes represent biologically plausible targets for neuroprotection, many additional patho logical processes can be implicated in disease progression, including innate or adaptive mediated inflam mation and inadequate remyelination. Thus, several explan ations could account for why amiloride, fluoxetine, and riluzole did not show efficacy in our study, including (but not restricted to) the ultimate relevance of the dynamic invivo disease processes primarily targeted by these three drugs. Indeed, our findings expose our incomplete knowledge of the pathobiology of secondary progressive multiple sclerosis.
Moreover, although evidence (clinical and MRI) for ongoing focal inflammatory disease activity in our study cohort was scant, we did not record any Bcell or microglial activity. In terms of phase 2 neuroprotection trials showing reductions in the rate of brain atrophy of 40-70%, use of diseasemodifying therapies has been between 0% and 45%. 7, 8, 30 In view of positive results from the ocrelizumab 4 and siponimod 3 phase 3 trials, future work will most likely stratify use of antiinflammatory com pounds in conjunc tion with possible neuroprotective agents.
The findings that fluoxetine was associated not only with a significantly higher PBVC at 24 weeks compared with placebo but also a concomitant decrease in the number of new or enlarging T2 lesions at 96 weeks should be interpreted with caution. These outcomes were secondary outcomes and the number of participants developing new or enlarging T2 lesion was, overall, low (mean 3·0 [SD 6·9] lesions; median 0 [IQR 0-2]).
Additionally, the MRI protocol did not include a post gadolinium scan at baseline and we were, therefore, unable to establish whether some of the patients allocated fluoxetine had, by chance, greater ongoing subclinical disease inflammatory activity at study entry. A paradoxical reduction in parenchymal brain volume compared with placebo (pseudoatrophy) has been well described 31, 35, 36 in both immunomodulatory (eg, natalizumab) 35 and sodium channel blockade (eg, lamotrigine) 31 studies. Fluoxetine might, therefore, exert a degree of immunomodulatory activity (eg, decreased lymphocyte proliferation and sup pressed interferonγ production) by acting on astrocytes; 37 findings of a small study showed reduction of new enhancing lesions in patients with relapsingremitting multiple sclerosis. 38 However, the primary outcome of our study at week 96 was negative and accords with the lack of therapeutic effect seen in the FLUOXPMS trial of 137 patients with progressive multiple sclerosis, which also did not show a beneficial effect on brain atrophy in a subgroup. 39 The MSSMART trial was restricted to patients with secondary progressive multiple sclerosis, with inclusion criteria as described. Generalisation to a wider population (eg, greater disability, older, or with primary progressive disease) is uncertain. Nonetheless, overall, we feel our study population will have mostly captured the secondary progressive clinical phenotype.
In conclusion, we have shown that a multiarm approach can be used successfully to expedite drug discovery in patients with progressive multiple sclerosis. Such trial designs will be highly relevant to future thera peutic develop ment in brain medicine in general. They are necessary to confirm or refute postulated pathways and give insight into the pathobiology of progressive multiple sclerosis.
Our results do not support the effectiveness of amiloride, fluoxetine, and riluzole in reducing disease progression for secondary progressive multiple sclerosis, and they indicate that exclusive targeting of axonal patho biology is an inadequate strategy to achieve neuro protection in pro gressive disease. In view of the need to develop diseasemodifying treatments for progressive multiple sclerosis, this finding challenges the area of research to shift towards combinatorial strategies or stratification based on greater resolution of relevant pathobiology at the level of indi vidual patients.
